Normal bone remodeling is a continuous process orchestrated by bone-resorbing osteoclasts and bone-forming osteoblasts, which an imbalance in bone remodeling results in metabolic bone diseases. RANKL, a member of the TNF cytokine family, functions as a key stimulator for osteoclast differentiation and maturation. Here, we report that RNF114, previously identified as a psoriasis susceptibility gene, plays a regulatory role in the RANKL/RANK/TRAF6 signaling pathway that mediates osteoclastogenesis. Our results demonstrated that RNF114 expression was significantly down-regulated in mouse osteoclast precursor cells undergoing RANKL-induced osteoclast differentiation. RNF114 knockout did not affect development or viability of the subpopulation of bone marrow macrophages capable of differentiating into osteoclasts in culture. However, in the presence of RANKL, RNF114 knockout bone marrow macrophages exhibited enhanced cell proliferation and augmented osteoclast differentiation, as shown by an increased expression of mature osteoclast markers, increased osteoclastic TRAP activity and bone resorption. Conversely, ectopic expression of RNF114 inhibited CTSK expression, TRAP activity, and bone resorption in RANKL-treated pre-osteoclasts. RNF114 also suppressed RANKL-activated NFATc1 expression and NFAT-regulated promoter activity. RNF114 suppressed TRAF6-, but not TAK1/TAB2-mediated NF-kB activation downstream of RANKL/RANK. In particular, TRAF6 protein levels were down-regulated by RNF114, possibly via K48-mediated proteasome-dependent degradation. These data suggested that RNF114's inhibitory effect on RANKLstimulated osteoclastogenesis was mediated by blocking RANK/TRAF6/NF-kB signal transduction. ß
Bone remodeling is a dynamic process involving continuous degradation of old bone by osteoclasts and generation of new bone by osteoblasts. Osteoclasts are multinucleated cells originating from the hematopoietic monocyte/macrophage linage. Their differentiation and maturation are regulated by cytokines, hormones, vitamins, ions, and extracellular matrix elements such as osteopontin and osteocalcin. Abnormally increased osteoclast activity disrupts the balance between bone breakdown and formation leading to diseases such as postmenopausal osteoporosis, Paget's disease, rheumatoid arthritis, and tumor-induced osteolytic bone destruction. [1] [2] [3] [4] Receptor activator of nuclear factor (NF)-kB ligand (RANKL) and its receptor RANK mediate signal transduction events that are responsible for differentiation of osteoclasts from their precursor cells and activation of the osteolytic function of mature osteoclasts. 5 RANKLÀ/À and RANKÀ/À mice showed severe osteopetrosis, a defect in bone resorption as a result of lack of activated osteoclasts. 6, 7 Overexpression of osteoprotegerin (OPG), an inhibitor of RANKL/ RANK signaling, resulted in increased bone mass due to decreased osteoclast numbers, 8 whereas OPG-deficient mice exhibited osteopenia. 9 Tumor necrosis factor (TNF) receptor-associated factor (TRAF) members share a conserved TRAF domain. They function as adaptor proteins that are recruited to a variety of receptor complexes to coordinate delivery of signals to downstream kinases or transcription factors. 10 One TRAF family member, TRAF6, plays a central role in RANKL/RANK signaling. TRAF6 interacts with transforming growth factor beta activated kinase 1 (TAK1) protein via TAK1-associated binding protein 2 (TAB2). Activated TAK1 then phosphorylates and activates the inhibitor of NFkB (IkB) kinase (IKK) leading to IkB degradation and activation of NF-kB. 11 TRAF6 is an E3 ubiquitin ligase that regulates signal transduction by ubiquitinating downstream regulators via lysine 48 (K48) conjugation, usually causing proteasomal degradation of the ubiquitinated protein, or via lysine 63 (K63) that often leads to protein activation or generation of a scaffold for downstream binding partners. Upon stimulation with RANKL, IL-1 or LPS, TRAF6 undergoes K63-linked autoubiquitination and promotes poly-ubiquitination of other downstream signaling molecules. 12 Ubiquitination mediated by TRAF6 is regulated by cylindromatosis (CYLD), 13 a deubiquitinating enzyme (DUB) that removes ubiquitin residues from signaling components involved in activating NF-kB. RANKLinduced osteoclast differentiation was up-regulated in CYLDÀ/À mice. 13 Another negative regulator of osteoclastogenesis, Itchy E3 ubiquitin protein ligase (Itch), interacts with CYLD to deubiquitinate TRAF6 to inhibit RANKL-induced osteoclast maturation. 14 RNF114 was first identified as a novel psoriasis susceptibility gene. 15 It shares structural similarity with RNF125, RNF138, and RNF166: an N-terminal RING (Really Interesting New Gene) finger domain followed by three zinc fingers and an ubiquitin interaction motif (UIM). 16 The RING domains are essential for the E3 ubiquitin ligase function of RNF125 and RNF138. [16] [17] [18] RNF125 suppressed RIG-I-like helicase (RLH)-mediated induction of type I interferon (IFN) through inhibitory (K48) poly-ubiquitination of signaling components. 19 Although not fully characterized, RNF114 may also play a role in regulating dsRNAinduced production of type I IFN via RLH signaling pathway (Lin et al., Submitted) [20] [21] [22] or as a regulator of T cell activation. 23 Here, we report that RNF114 inhibited RANKLinduced osteoclast differentiation and activation as a negative feedback in response to RANKL, in a preosteoclast cell line RAW 264.7 and in a more physiologically relevant system of primary RNF114 knockout mouse osteoclast precursors. It blocked the activation of NF-kB by promoting proteasomal degradation of TRAF6. These data suggested that RNF114 plays a regulatory role in both immune/inflammatory responses and in bone metabolism.
METHODS

Cell Lines, Plasmids, and Reagents
Mouse leukemic monocyte/macrophage cell line RAW 264.7 and human embryonic kidney (HEK) 293 cell line (both from ATCC, Manassas, VA) were maintained in Dulbecco's modified Eagle's medium (DMEM) (HyClone, Logan, UT) supplemented with 10% fetal calf serum, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. Expression plasmids for mouse and human RNF114 were developed by inserting the cDNA sequences into the pcDNA3.1 vector in-frame with C-terminal Myc and His tags. Human TRAF6 cDNA was cloned into a p3XFLAG-CMV vector. Plasmids expressing TAK1 and TAB2 were gifts from K. Yeung (University of Toledo, OH, USA). NFAT-Luc reporter plasmid was a gift from S. Reddy (Medical University of South Carolina, SC, USA), and 3XkB-Luc reporter plasmid was a gift from B. Ashburner (University of Toledo, OH, USA). Mouse recombinant RANKL and M-CSF were purchased from Invitrogen (Carlsbad, CA), MG132, anti-Actin monoclonal antibody and anti-FLAG monoclonal antibody from Sigma-Aldrich (St. Louis, MO), and anti-Myc monoclonal antibody from Santa Cruz Biotechnology (Dallas, TX). Lipofectamine 2000 (Invitrogen) and PolyJet (SignaGen, Gaithersburg, MD) were used for transfection for RAW 264.7 and HEK293, respectively. , and bone marrow cells from femurs were collected by flushing cells out of the marrow cavity using a syringe with a 25G needle and cultured on Petri dishes in DMEM supplemented with 10% fetal calf serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin, and 20 ng/ ml M-CSF for 7 days. To induce osteoclast differentiation of BMMs, cells were re-seeded in 24-well tissue culture plates and stimulated with 50 ng/ml RANKL and 20 ng/ml M-CSF. Three female and three male animals were used, and since no significant difference between sexes was observed, data presented here were based on studies on three male mice. To confirm the osteoclastogenic potential of the cells, BMMs of wild-type or RNF114 KO were counted, pre-treated with TruStain fcX to block Fc receptors, incubated with PE-CD115 and PE/Cy5-CD117 antibodies, and detected using a BD FACSCalibur (San Jose, CA). All antibodies were purchased from Biolegend (San Diego, CA).
Mouse
Cell Viability Assay
BMMs maintained in M-CSF-containing DMEM were seeded in a 24-well plate and treated with 50 ng/ml RANKL for 24 or 48 h or left untreated. To assess the cell viability, the cells were incubated in 1 mg/ml thiazolyl blue tetrazolium bromide (MTT, Sigma-Aldrich) for 4 h, the insoluble formazan dissolved in DMSO, and the optical density measured at 590 nm wavelength.
Osteoclast Differentiation and Activity Assays
Osteoclast precursors generated from wild-type or RNF114 KO BMMs were seeded in 6-well plates, cultured in DMEM supplement with 20 ng/ml M-CSF, and stimulated with or without 50 ng/ml RANKL. After 7 days, the cells were washed with PBS and lysed with 50 mM sodium acetate buffer (pH 7.4) containing 0.1% Triton X-100. To measure the activity of tartrate-resistant acid phosphatase (TRAP), the substrate solution (125 mM sodium acetate buffer [pH 5.2] containing 1 mM sodium tartrate and 100 mM p-nitrophenyl phosphate) was added into the lysate followed by 30 min incubation at 37˚C. The reaction was stopped by adding 0.1 N NaOH, and the absorbance measured at 405 nm. The optical density was first normalized to the cell viability measured by the MTT assay, and the TRAP activity was expressed as a fold change relative to the untreated control. Some cells were harvested for mRNA extraction and subjected to real-time RT PCR analysis to assess cathepsin K (CTSK) and nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) expression, markers of osteoclast differentiation.
The bone resorptive activity of osteoclasts was measured by using a Bone Resorption Assay Kit (Cosmo Bio, Carlsbad, CA). Mouse osteoclast precursors were seeded in a fluoresceinamine-labeled chondroitin sulfate/calcium phosphatecoated 24-well plate, and osteoclast differentiation induced by 50 ng/ml RANKL. After a culture period of 14 days, the plate was processed and the bone resorption was measured according to the manufacturer's instructions. The intensity of fluorescence was first normalized to the cell viability measured by the MTT assay, and the bone resorptive activity was expressed as a fold change relative to the untreated control. To investigate the effect of RNF114 over-expression, similar experiments were carried out using RAW 264.7 transfected with a RNF114-expressing plasmid or an empty vector with or without a 7-day treatment of 50 ng/ml RANKL.
Luciferase Reporter Assays RAW 264.7 cells were transfected with a mouse NFAT-Luc reporter plasmid with or without a mouse RNF114-expressing plasmid. A SV40 b-galactosidase-expressing plasmid was also co-transfected to serve as an internal control for transfection efficiency. These cells were cultured in the presence or absence of RANKL (100 ng/ml) for 36 h and then lysed in Reporter Lysis Buffer (Promega, Madison, WI) for luciferase activity assessment. Relative light unit readings were normalized to b-galactosidase activity and expressed as a fold change to the untreated control.
To assess NF-kB transcriptional activity, HEK293 cells were co-transfected with a 3XkB-Luc reporter plasmid, an SV40 b-galactosidase-expressing plasmid, and plasmids expressing proteins of interest. After 24 h, luciferase assays were performed as described above.
Quantitative Real-Time RT-PCR Cellular RNA was isolated using TRIzol reagent (Invitrogen) and reverse transcribed to cDNA using M-MLV reverse transcriptase (Promega). The Quantitative real-time RT-PCR was performed utilizing SsoFast EvaGreen Supermix (BioRad, Hercules, CA) and a 2-step amplification program (30 s at 95˚C and 60 s at 62˚C) on a thermal cycler. The mRNA level of the gene of interest was normalized to Actin mRNA and calculated based on the D(DCt) method. Primer sequences: CTSK (For:
Immunoblot Analysis
Cells were lysed in a lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% TRITON X-100 and proteasome inhibitor cocktail) on ice followed by centrifugation to remove cell debris. Proteins in the lysates were separated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes and immunoblotted with antibodies specific for the proteins of interest.
Statistical Analysis
For quantitative data presented graphically, the mean AE standard deviations were calculated based on at least three separate experiments under the same conditions. Student's ttests were used to compare data pairs and the degree of significance (p-value) indicated in the figure legends.
RESULTS
RAW 264.7 macrophage cells can differentiate to osteoclast-like cells in response to RANKL stimulation. Steady state RNF114 mRNA levels were down-regulated markedly after stimulating RAW 264.7 with 50 ng/ml RANKL for 3 or 7-days (Fig. 1a, left) , an effect that was inversely correlated with CTSK expression (Fig. 1a, right) , which serves as an indicator for the osteoclast differentiation. 24 RANKL treatment also decreased RNF114 mRNA expression in mouse bone marrow-derived macrophages (BMMs) (Fig. 1b, left) , once again in contrast to CTSK mRNA levels (Fig. 1b,  right) . Subpopulations of murine bone marrow cells 
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161 that express higher levels of the hematopoietic markers CD115 and CD117 are more potent osteoclast precursors 25 ; however, no significant differences in cell populations of CD115þ/CD117þ/RNF114þ/þ and CD115þ/CD117þ/RNF114À/À BMMs were observed (13% vs. 12.61%) (Fig. 2a) . To investigate the effect of RNF114 on BMM cell survival, RNF114 KO and wildtype mouse BMMs were cultured for 24 or 48 h and cell viability assessed. Cell survival was not different between wild-type and RNF114À/À BMMs in the absence of RANKL, but when the cells were treated with this ligand, RNF114À/À BMMs exhibited significantly enhanced proliferation as compared to the wildtype BMMs (Fig. 2b) . These results suggested that RNF114 does not impact development of osteoclast precursors derived from BMM, but may negatively regulate RANKL-mediated cell proliferation.
To investigate a role for RNF114 in osteoclast differentiation, RANKL-treated wild-type and RNF114À/À BMMs were analyzed by real-time RT PCR for CTSK and NFATc1 expression. They were also subjected to TRAP enzyme activity and bone resorption assays. After treatment with RANKL for 7 days, CTSK, which is expressed predominantly in mature osteoclasts, and NFATc1, the master transcription factor for osteoclast differentiation, were both elevated in RNF114 KO cells (Fig. 3a, Supplement  Fig. S1a) . TRAP enzyme activity, a common indicator of activated osteoclasts, was measured by using pnitrophenyl phosphate as a substrate. RANKL-stimulated RNF114À/À BMMs showed increased TRAP activity as compared to wild-type cells (Fig. 3b , Supplement Fig. S1b ). To evaluate osteoclastic boneresorbing activity, BMMs of both genotypes were seeded onto fluoresceinamine-labeled chondroitin sulfate/calcium phosphate-coated plates followed by a 14-day RANKL treatment. Fluorescence intensity was measured to quantify bone resorption. The results indicated that RNF114À/À cells exhibited increased bone resorptive activity as compared to wild-type cells (Fig. 3c, Supplement Fig. S1c) . Together, our data suggested that RNF114 functioned as a negative regulator of RANKL-induced osteoclast differentiation.
A regulatory role for RNF114 in RANKL-induced osteoclast differentiation was tested under conditions of RNF114 over-expression. Pre-osteoclast RAW 264.7 cells were transiently transfected with a plasmid expressing RNF114 or with empty vector, followed by RANKL stimulation. Activated osteoclasts were assayed for CTSK and NFATc1 mRNA levels as well as TRAP enzymatic and bone resorptive activities. Ectopic RNF114 expression inhibited RANKL-induced CTSK and NFATc1 expression (Fig. 4a) , and also suppressed maturation of osteoclasts, as illustrated by the observed decrease in TRAP activity (Fig. 4b) and osteolysis (Fig. 4c) . Auto-amplification of NFATc1 prolongs signals to promote osteoclastogenesis. Luciferase assays using a NFAT-dependent luciferase reporter indicated that increased RNF114 also attenuated NFAT activation following RANKL stimulation (Fig. 5) .
RANKL signals through the RANK/TRAF6/NF-kB pathway to activate osteoclast differentiation. To assess RNF114 impact on this pathway, HEK293 cells were transiently transfected with a NF-kB-dependent luciferase reporter, along with expression plasmids for TRAF6, TAB2/TAK1 and/or RNF114. After 24 h, cells were harvested, and luciferase assays performed. RNF114 inhibited TRAF6 but not TAB2/TAK1 activation of NF-kB (Fig. 6a) . TRAF6 protein levels were reduced when co-transfected with RNF114 (Fig. 6b,  left) , an effect that was proteasome-dependent since addition of the proteasome inhibitor MG132 attenuated TRAF6 reduction and led to accumulation of its ubiquitinated products (Fig. 6b, right) . These data suggested that RNF114 negatively regulated osteoclast differentiation, at least in part, by blocking TRAF6-mediated NF-kB activation. The immunoprecipitation studies did not show a direct interaction between RNF114 and TRAF6, TAB2, or TAK1 (data not shown), suggesting that its effects were either indirect or that its association with TRAF6-containing signaling complexes was transient.
DISCUSSION
We report a novel inhibitor of osteoclastogenesis, RNF114, which was previously implicated in innate immune regulation. [20] [21] [22] [23] Our results demonstrated Figure 3 . Silencing of RNF114 augmented RANKL-induced osteoclast differentiation and bone resorption. After 7 day treatment with RANKL, osteoclast precursors generated from WT or RNF114 KO BMMs were harvested to assess (a) CTSK and NFATc1 expression by real-time RT PCR, normalized to the actin level, and (b) TRAP activity. TRAP activity was assessed using a substrate solution containing p-nitrophenyl phosphate and was normalized to cell viability, which was determined in cells treated in parallel using an MTT assay. (c) The bone resorption activity of osteoclasts was assessed by measuring the release of fluoresceinated calcium phosphate from precoated 24-well plates, with or without RANKL, for 14 days. The intensity of fluorescence was normalized to cell viability. All data were expressed as a fold change relative to untreated controls. The mean and SEM were calculated based on three independent experiments. ( ÃÃ p < 0.01, Ã p < 0.05).
Figure 4.
Overexpression of RNF114 inhibited RANKL-induced osteoclast differentiation and bone resorption. RAW 264.7 cells were transiently transfected with RNF114 or empty vector followed by 5 day RANKL treatment, and then assessed for (a) CTSK and NFATc1 mRNA expression by using real-time RT PCR, normalized to the actin level, and (b) TRAP activity by using a substrate solution containing p-nitrophenyl phosphate, normalized to the cell viability as in Figure 3 . (c) The bone resorption activity of osteoclasts was assessed by measuring the release of fluoresceinated calcium phosphate with or without RANKL for 7 days. The intensity of fluorescence was normalized to cell viability. All data were expressed as a fold change relative to untreated controls. The mean and SEM were calculated based on three independent experiments. ( Ã p < 0.05).
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163 that RNF114 expression was significantly down-regulated in a macrophage cell line and mouse primary BMMs when these osteoclast precursors underwent RANKL-induced osteoclast differentiation and activation. In RNF114 KO mouse bone marrow, the subpopulation of BMMs capable of differentiating into osteoclasts developed normally and was viable in culture. However, in the presence of RANKL, RNF114 KO BMMs exhibited enhanced proliferation (quantified by MTT cell viability assays) and augmented osteoclast differentiation (i.e., increased expression of mature osteoclast markers such as CTSK, increased osteoclastic TRAP activity and bone resorption) as compared to wild-type BMMs. Conversely, ectopic expression of RNF114 inhibited CTSK expression, TRAP activity, and bone resorption in RANKLtreated pre-osteoclast RAW 264.7 cells. RNF114 also suppressed RANKL-activated NFATc1 expression and NFAT-regulated promoter activity. A role for RNF114 in regulating osteoclastogenesis was assessed by investigating its impact on signaling molecules downstream of RANKL/RANK. Luciferasebased assays suggested that RNF114 suppressed TRAF6, but not TAK1/TAB2-mediated NF-kB activation. In co-transfection studies, TRAF6 proteins levels were inversely correlated with RNF114 levels, an effect that was blocked when the cells were treated with MG132. In these cells, TRAF6 degradation was inhibited, and ubiquitinated TRAF6 accumulated, suggesting that RNF114 may be involved in K48-mediated proteasome-dependent degradation of TRAF6. These data indicated that RNF114's inhibitory effect on RANKL-stimulated osteoclast maturation may have resulted from its ability to suppress RANK/TRAF6/NF-kB signal transduction. Since we could not observe direct interaction between RNF114 and TRAF6, the details of how RNF114 regulates TRAF6 turnover is still under investigation.
There is growing interest in understanding the crosstalk between bone regeneration and immune/ inflammatory responses. In the case of bone fractures, the effects of cytokines generated from immune cells can be both harmful (by attenuating bone repair) and beneficial (by preventing infection). A balance between these opposing outcomes is likely achieved by close communication between signaling networks regulating defense mechanisms and reparative potential. RANKL plays a critical role in immune activation, immunological tolerance, and lymphoid organogenesis 26 and also possesses pro-osteoclastogenic properties. RANKL fosters inflammatory responses and bone resorption via a pathway sharing key signaling molecules (e.g., TRAF6 and NF-kB). 27 Negative regulators of the RANK pathway, such as CYLD 13, 28 and Itch 14, 29 are shared with other cytokine responses, and depending on the cell types, can act specifically to block immune/inflammatory responses or to suppress osteoclast differentiation and activation. Here, we describe RNF114 as another possible inhibitor. Recent studies suggested that RNF114 can bind to A20 to modulate NF-kB activity and T-cell activation, 30 and A20-mediated recruitment and inactivation of receptor-interacting serine/threonine-protein kinase (RIP) 1 can be controlled by Itch to terminate TNF receptor signaling.
29
RNF114's indirect effect on TRAF6 may be via interacting and stabilizing A20, which was shown associated with TRAF6 degradation. 31 Other cytokine signaling pathways also impact bone metabolism and can potentially be targeted by RNF114. For example, mice with IFNb deficiency exhibited severe bone loss associated with osteoclastogenesis. 32 RNF125, a close relative of RNF114, is a potent negative regulator of IFNb production. 19 Direct or indirect regulation of cytokine responses and bone remodeling by RNF114 and/or RNF125, and their related family members, remains an unexplored area of signaling research.
Surprisingly, the population of osteoclast precursors was not affected by RNF114 KO (Fig. 2a) , and KO mice were viable without obvious phenotypic abnormalities in bone and lifespan. Perhaps other more abundant or potent negative regulators of this signal pathway can compensate for RNF114's function. In our ex vivo studies, we have demonstrated that RNF114 counteracted with excess RANKL applied to create pathological conditions leading to an imbalance in bone metabolism. Therefore, the effect of RNF114 may be more profound in a disease model. In conclusion, our data implicated RNF114 as a negative regulator of RANKL-dependent signaling in osteoclast maturation and bone resorption. RNF114's inhibition appeared to be through its regulation of TRAF6 proteasome degradation; however, the precise mechanism has not yet been characterized.
